Nonhormonal therapy for endometriosis: a randomized, placebo-controlled, pilot study of cabergoline versus norethindrone acetate
Authors:
Open Access
- 24 July 2021
- journal article
- research article
- Published by Elsevier in F&S Reports
- Vol. 2 (4) , 454-461
Abstract
No abstract availableKeywords
Funding Information
- J. Willard and Alice S. Marriott Foundation
- Merck
This publication has 56 references indexed in Scilit:
- Side effects of anti-angiogenic drugsThrombosis Research, 2012
- Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countriesFertility and Sterility, 2011
- Clinical utility and validity of the Functional Disability Inventory among a multicenter sample of youth with chronic painPain, 2011
- VEGF Inhibition and Renal Thrombotic MicroangiopathyNew England Journal of Medicine, 2008
- Pregnancy outcomes following cabergoline treatment: extended results from a 12‐year observational studyClinical Endocrinology, 2007
- Antiangiogenic therapies in endometriosisBritish Journal of Pharmacology, 2006
- ACOG Committee Opinion #310: Endometriosis in AdolescentsObstetrics & Gynecology, 2005
- Ablation of Peripheral Dopaminergic Nerves Stimulates Malignant Tumor Growth by Inducing Vascular Permeability Factor/Vascular Endothelial Growth Factor-Mediated AngiogenesisCancer Research, 2004
- Pregnancy outcome after treatment with the ergot derivative, cabergolineReproductive Toxicology, 1996
- Impact of gestrinone on the course of asymptomatic endometriosis.BMJ, 1987